Furthermore, comparative studies between RASD2 silencing and established glycolysis inhibitors would help position RASD2‐targeted therapy within the broader landscape of metabolic interventions in thyroid cancer. The gene discussed is RASD2; the disease is thyroid gland carcinoma.